Brazil vs Honduras: Average cost of multi drug-resistant tuberculosis treatment
Brazil
4,102 constant 2022 US$
in 2024
Honduras
3,743 constant 2022 US$
in 2024
Brazil rank
10th
Honduras rank
11th
Average cost of multi drug-resistant tuberculosis treatment over time
- Brazil
- Honduras
How they compare
Brazil currently reports 4,102 constant 2022 US$ against 3,743 constant 2022 US$ in Honduras, a difference of 359 constant 2022 US$.
That makes Brazil's figure about 1.1 times Honduras's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Brazil ahead.
Brazil ranks 10th and Honduras ranks 11th of 92 countries.
Brazil has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Brazil | Honduras | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,620 constant 2022 US$ | 1,711 constant 2022 US$ | 909.33 constant 2022 US$ | Brazil |
| 2020s | 4,011 constant 2022 US$ | 1,891 constant 2022 US$ | 2,120 constant 2022 US$ | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Brazil or Honduras?
- Brazil, at 4,102 constant 2022 US$ against 3,743 constant 2022 US$ in Honduras as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Brazil and Honduras?
- 359 constant 2022 US$, with Brazil ahead.
- How many years of comparable data are there for Brazil and Honduras?
- 8 years are reported by both, from 2017 to 2024.
- How do Brazil and Honduras rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Brazil ranks 10th and Honduras ranks 11th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.